Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437602 | 0.90 | ALDH1A1 (0.51) | PRCPHSD17B10ALDH1A1TSHREPHX2 | |
| SCHEMBL17437601 | 0.90 | ALDH1A1 (0.51) | PRCPHSD17B10ALDH1A1TSHREPHX2 | |
| SCHEMBL18761565 | 0.74 | PRCP (0.49) | PRCPHTR2CHTR2AHTR2BTLR2 | |
| SCHEMBL615383 | 0.71 | PRCP (0.68) | PRCPHTR2CHTR2AHTR2BTLR2 | |
| SCHEMBL496387 | 0.71 | PRCP (0.68) | PRCPHTR2CHTR2AHTR2BTLR2 | |
| SCHEMBL616732 | 0.71 | PRCP (0.68) | PRCPHTR2CHTR2AHTR2BTLR2 | |
| Hydrochloric Acid SCHEMBL4320225 | 0.70 | PRCP (0.66) | PRCPHTR2CHTR2AHTR2BTLR2 | |
| SCHEMBL12529945 | 0.70 | PRCP (0.57) | PRCPHTR2CHTR2AHTR2BTLR2 | |
| SCHEMBL15329272 | 0.69 | PRCP (0.70) | PRCPHTR2CHTR2AHTR2BTLR2 | |
| SCHEMBL943040 | 0.68 | PRCP (0.58) | PRCPHTR2CHTR2AHTR2BTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | PRCP 3660/4885HSD17B10 2950/4885ALDH1A1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.